

NC Pharmacy Prior Approval Request for Hetlioz/Hetlioz LQ

Beneficiary Information _____2. First Name: _____ 1. Beneficiary Last Name: 3. Beneficiary ID #: ______ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: ____ Prescriber Information 6. Prescribing Provider NPI #: _____ Provider Fax #: _____ Provider Fax #: _____ Ext. ____ Drug Information 8. Drug Name: 11. Length of Therapy (In days): Initial Request: □ up to 30 Days □ 60 Days □ 90 Days Re-authorization: ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days Clinical Information **HETLIOZ** (complete questions 1-6 for Helioz) 1. Is the beneficiary 18 years old or older? \square Yes \square No 2. Does the beneficiary have a documented diagnosis of Non-24 sleep-wake disorder? ☐ Yes ☐ No 3. The diagnosis of Non-24 sleep-wake disorder is confirmed by meeting ONE of the following conditions: ☐ Assessment of at least one physiologic circadian phase marker (e.g., measurement of urinary melatonin levels, dim light melatonin onset [as measured in blood or saliva], assessment of core body temperature ☐ Assessment of at least one physiologic circadian phase marker cannot be done, the diagnosis must be confirmed By actigraphy performed for >/= 1 week plus evaluation of sleep logs recorded for >/= 1 month 4. Is the beneficiary 16 years old or older? ☐ Yes ☐ No 5. Does the beneficiary have a diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)? ☐ Yes ☐ No **HETLIOZ LQ** (complete questions 7-8 for Hetlioz LQ) 7. Is the beneficiary between 3 years and 15 years of age? ☐ **Yes** ☐ **No** 8. Does the beneficiary have a diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)? ☐ Yes ☐ No Hetlioz and Hetlioz LQ: (complete guestions 9-10) 9. Has the beneficiary had an insufficient response or intolerance to at least two (2) other medications for sleep? (can be over-thecounter or prescription) ☐ Yes ☐ No 10. Is this medication being prescribed by, or is the physician consulting with, a physician who specialized in the treatment of sleep Re-authorization for Hetlioz and Heltioz LQ: (complete questions 11-12) 11. Has the beneficiary used Hetlioz/Hetlioz LQ continuously without gaps in treatment for the initial approval period of three (3) months? ☐ Yes ☐ No 12. As the provider, have you included an objective evaluation of the beneficiary's sleep quality, including documentation of an improvement in overall sleep quality while taking Hetlioz/Hetlioz LQ?

Yes

No **Documentation of the beneficiary's overall sleep quality improvement must accompany this reauthorization for Hetlioz/Hetlioz LQ. **

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Pharmacy PA Call Center: 1-855-258-1593

Signature of Prescriber: